IOL Chemicals posts robust Q3 & 9M FY26 results, PBT up 39% YoY
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
The program provides pharmaceutical manufacturers with auditable, primary emissions data and verified proof of a 30% CO? reduction across DFE Pharma’s lactose portfolio
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
U.S. market achieved record quarterly sales of Rs. 3,113.2 crore ($350 million), a 54% YoY increase, accounting for 44% of global sales
Occlutech develops, manufactures, and commercialises medical devices for congenital heart disease, stroke prevention, and heart failure
Signed Memorandum of Understanding supports "Plan Mexico," Mexico's strategic initiative to build a local mRNA ecosystem and strengthen health security
The pharmaceutical segment led growth, generating Rs. 337 crore in revenue, while the crop protection business contributed Rs. 157 crore
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
Subscribe To Our Newsletter & Stay Updated